duchenn
muscular
dystrophi
dmd
genet
xlink
recess
orphan
diseas
affect
approxim
male
birth
boy
dmd
progress
predict
muscl
destruct
due
absenc
dystrophin
protein
present
muscl
fi
ber
membran
absenc
induc
contractionrel
membran
damag
activ
infl
ammatori
necrosi
fi
brosi
lead
cardiac
diaphragmat
failur
death
author
support
therapeut
role
myoblast
transplant
dmd
describ
histori
rational
approach
tissu
affect
genet
diseas
clinic
feasibl
review
base
year
experiment
background
howev
defi
nite
transplant
protocol
yet
establish
owe
delay
perform
phase
clinic
trial
aim
articl
therefor
stress
opportun
offer
mt
restor
function
genet
damag
muscl
urg
dedic
team
surgeon
biologist
perform
clinic
trial
demonstr
longterm
benefi
ts
procedur
defi
nitiv
revers
muscl
damag
without
repeat
allogen
transplant
duchenn
muscular
dystrophi
fatal
hereditari
diseas
current
treatment
progress
muscl
weak
start
age
year
thu
lead
wheelchair
confi
nement
age
death
respiratori
complic
secondari
heart
diseas
age
year
duchenn
muscular
dystrophi
caus
xlink
genet
defect
lead
absenc
dystrophin
dy
absenc
dystrophin
plasma
membran
make
muscl
fi
ber
vulner
contract
damag
muscl
fi
ber
present
soon
child
born
demonstr
high
creatinin
kinas
ck
level
serum
follow
releas
damag
muscl
fi
ber
damag
fi
ber
repair
prolifer
fusion
peripher
stemcelllik
cell
call
satellit
cell
satellit
cell
call
myoblast
prolifer
unfortun
case
dmd
repair
muscl
fi
ber
still
lack
dystrophin
thu
remain
vulner
subsequ
contract
lead
repeat
cycl
damag
repair
cycl
satellit
cell
prolifer
gener
myoblast
repair
frequent
cycl
prolifer
lead
senesc
result
progress
loss
regen
potenti
age
year
indic
progress
diffi
culti
age
prolifer
myoblast
muscl
biopsi
dmd
patient
therefor
damag
muscl
fi
ber
longer
adequ
repair
thereaft
becom
progress
replac
fat
conjunct
tissu
variou
type
cell
investig
cell
therapi
muscular
dystrophi
subject
recent
review
among
cell
freshli
isol
satellit
cell
myoblast
prolifer
vitro
satellit
cell
mesoangioblast
pericyt
pluripot
cell
call
musclederiv
stem
cell
mdsc
cellular
therapi
take
advantag
fact
variou
type
cell
deriv
healthi
donor
carri
normal
dystrophin
gene
fuse
damag
dmd
muscl
fi
ber
fusion
introduc
normal
dy
exist
muscl
fi
ber
protect
damag
inde
transplant
wildtyp
syngen
myoblast
shown
earli
restor
dy
express
immunodefi
cient
mdx
mice
model
dmd
good
transplant
result
also
obtain
differ
research
group
mdx
mice
immunosuppress
cyclosporin
tacrolimu
success
myoblast
transplant
mt
mice
led
investig
mt
monkey
immun
system
size
bicep
muscl
compar
human
tacrolimu
treatment
also
prevent
reject
mt
fi
ber
throughout
entir
bicep
monkey
hybrid
origin
month
mt
hybrid
fi
ber
present
one
year
mt
clearli
demonstr
transplant
myoblast
fuse
effi
cientli
normal
muscl
fi
ber
primat
earli
clinic
trial
myoblast
transplant
duchenn
becker
muscular
dystrophi
done
patient
younger
year
unfortun
produc
limit
posit
result
period
karpati
et
al
transplant
million
allogen
normal
myoblast
throughout
bicep
eight
young
dmd
patient
immunosuppress
cyclophosphamid
month
detect
increas
express
dystrophin
muscl
biopsi
patient
two
year
later
research
group
demonstr
absenc
success
clinic
trial
due
fact
cyclophosphamid
kill
prolifer
cell
includ
myoblast
gussoni
et
al
transplant
million
myoblast
eight
dmd
patient
age
year
administ
cyclosporin
immunosuppress
report
express
normal
dystrophin
transcript
muscl
biopsi
obtain
month
transplant
three
patient
gussoni
et
al
reexamin
muscl
biopsi
six
dmd
patient
year
later
use
fl
uoresc
situ
hybrid
fish
base
method
donor
nuclei
detect
biopsi
analyz
includ
nine
donor
myoblast
previous
thought
present
three
patient
show
origin
number
donor
cell
present
month
implant
half
detect
donor
nuclei
fuse
host
myofib
nearli
produc
dystrophin
fi
nding
demonstr
although
donor
myoblast
persist
inject
microenviron
infl
uenc
whether
fuse
express
dystrophin
mendel
group
inject
million
donor
myoblast
month
month
total
million
myoblast
bicep
brachii
muscl
one
arm
dmd
boy
age
year
immunosuppress
throughout
period
cyclosporin
transplant
session
myoblast
inject
site
mm
apart
distribut
row
column
observ
dystrophinposit
fi
ber
patient
howev
abl
demonstr
dystrophin
donor
origin
presenc
dystrophin
epitop
code
exon
delet
patient
genom
year
later
hong
et
al
demonstr
mice
cyclosporin
block
differenti
induc
myoblast
apoptosi
earli
stage
muscl
differenti
probabl
account
poor
result
obtain
clinic
trial
use
immunosuppress
drug
group
transplant
myoblast
obtain
perfectli
human
leukocyt
antigencompat
donor
assum
immunosuppress
treatment
would
requir
dystrophinposit
fi
ber
observ
patient
howev
possibl
demonstr
fi
ber
donor
origin
patient
identifi
ed
delet
select
fi
rst
clinic
trial
also
detect
presenc
antibodi
dystrophin
subsequ
studi
demonstr
transplant
major
histocompat
complexcompat
myoblast
without
immunosuppress
led
reject
due
minor
antigen
mice
experi
anim
model
permit
identifi
cation
two
addit
problem
earli
clinic
trial
fi
rst
problem
myoblast
migrat
away
inject
trajectori
thu
high
densiti
inject
requir
obtain
high
percentag
hybrid
fi
ber
second
problem
high
percentag
transplant
cell
die
fi
rst
day
follow
transplant
therefor
million
myoblast
inject
per
cm
muscl
obtain
good
transplant
result
monkey
earli
mt
clinic
trial
produc
best
limit
result
inadequ
immunosuppress
insuffi
cient
number
transplant
cell
insuffici
distribut
cell
recent
clinic
trial
transplant
myoblast
cm
muscl
followup
tacrolimu
immunosuppress
month
clinic
trial
demonstr
transplant
normal
allogen
myoblast
restor
express
dystrophin
muscl
fi
ber
within
cm
inject
site
concurr
compassion
treatment
patient
restor
express
dystrophin
muscl
fi
ber
observ
made
cm
muscl
biopsi
howev
muscl
transplant
myoblast
throughout
volum
thu
muscl
biopsi
probabl
refl
ect
result
would
obtain
throughout
muscl
smalldiamet
muscl
fi
ber
appar
complet
donor
origin
observ
recent
clinic
trial
importantli
transplant
myoblast
fuse
immedi
remain
quiescent
satellit
cell
abl
repair
subsequ
damag
induc
normal
muscl
activ
morgan
group
recent
demonstr
myoblast
transplant
mdx
mous
muscl
expand
follow
muscl
biopsi
retranspl
success
suggest
function
satellit
cell
recent
result
confi
rmed
donor
cell
satellit
cell
posit
mice
posit
myod
neg
confi
rming
satellit
cell
unpublish
result
moreov
donor
cell
also
observ
satellit
cell
posit
muscl
biopsi
patient
particip
clinic
trial
unpublish
result
sever
approach
current
pursu
treatment
dmd
gene
therapi
aim
introduc
dy
gene
directli
patient
muscl
fi
ber
howev
form
gene
therapi
prolong
gene
express
avoid
host
immun
respons
vector
widespread
distribut
remain
problemat
inde
like
viral
vector
treat
dmd
current
adenoassoci
viru
aav
howev
chamberlain
group
recent
report
immun
respons
aav
vector
dog
suggest
immunosuppress
may
requir
eventu
clinic
trial
moreov
aav
vector
contain
truncat
version
dystrophin
gene
call
microdystrophin
newli
express
protein
differ
truncat
endogen
version
dystrophin
present
fi
ber
patient
socal
revert
fi
ber
caus
somat
mutat
lead
skip
one
sever
exon
possibl
new
junction
peptid
may
provok
immunolog
reaction
neoantigen
sinc
microdystrophin
differ
patient
revert
dystrophin
new
approach
gene
therapi
base
exon
skip
bypass
mutant
stop
codon
allow
express
truncat
dy
like
result
milder
diseas
phenotyp
seen
becker
form
dystrophi
moreov
sinc
dy
express
may
ident
endogen
express
rare
revert
fi
ber
immunogen
might
avoid
develop
toler
presenc
revert
fi
ber
yet
proven
howev
uncertainti
remain
longterm
potenti
toxic
morpholino
oligonucleotid
use
induc
exon
skip
degrad
cell
may
thu
eventu
accumul
nuclei
moreov
exon
skip
solut
dmd
patient
sever
recess
dystrophi
although
mesoangioblast
blood
vesselderiv
cell
may
deliv
system
restor
express
dystrophin
dystroph
dog
intramuscular
deliveri
myoblast
proven
effect
safe
dmd
patient
given
anoth
treatment
proven
effect
patient
direct
intramuscular
myoblast
transplant
may
use
increas
strength
specifi
c
muscl
dmd
muscular
dystrophi
local
muscl
weak
evid
support
benefi
cial
effect
mt
damag
observ
dysneg
fi
ber
dysposit
fi
ber
result
mt
mdx
mice
subject
eccentr
exercis
month
follow
mt
therefor
mt
protect
muscl
tissu
mdx
mice
mechan
stress
serv
trigger
myofi
ber
necrosi
dmd
moreov
graft
myoblast
also
shown
form
new
muscl
fi
ber
mous
model
group
current
tri
conduct
second
clinic
trial
verifi
whether
mt
increas
strength
one
dmd
muscl
limit
impos
human
ethic
committe
regulatori
agenc
current
postul
clinic
trial
aim
transplant
myoblast
singl
small
muscl
extensor
carpi
radiali
employ
tacrolimu
immunosuppress
protocol
evalu
whether
procedur
improv
strength
muscl
howev
local
ethic
committe
current
restrict
clinic
trial
patient
older
year
moreov
regulatori
agenc
also
requir
dmd
patient
older
year
respir
seroposit
cytomegaloviru
cmv
restrict
justifi
ed
increas
risk
infect
risk
reactiv
cmv
greatli
limit
number
patient
particip
clinic
trial
sinc
dmd
patient
older
respir
adult
cmv
seroposit
duchenn
muscular
dystrophi
patient
older
year
advanc
stage
diseas
muscl
larg
infi
ltrate
fat
conjunct
tissu
make
demonstr
improv
strength
extrem
diffi
cult
function
preserv
improv
followup
would
wise
transplant
myoblast
muscl
patient
prevent
muscl
failur
maintain
adequ
immunosuppress
treatment
howev
current
ethic
regulatori
approv
includ
possibl
risk
associ
immunosuppress
therefor
justifi
ed
given
extrem
low
qualiti
life
dmd
patient
one
main
conceptu
object
mt
clinic
trial
concern
side
effect
immunosuppress
therapi
treatment
yet
proven
effect
increas
strength
patient
inde
averag
life
expect
dmd
new
technolog
respiratori
support
dedic
medic
care
year
therefor
even
qualiti
life
progress
deterior
due
impair
diaphragm
heart
muscl
human
ethic
committe
reluct
permit
even
period
immunosuppress
tacrolimu
potenti
advers
effect
associ
drug
increas
risk
cancer
diabet
neurotox
etc
ethic
committe
also
reluct
permit
inclus
young
dmd
patient
except
need
use
wheelchair
year
age
patient
usual
requir
specifi
c
medic
assist
philosophi
ethic
solid
organ
transplant
lifethreaten
organ
failur
justifi
es
risk
transplant
challeng
one
except
kidney
insuffi
cienci
dialysi
artifi
cial
kidney
support
provid
choic
avoid
transplant
price
poor
life
qualiti
intens
monitor
treatment
schedul
high
complic
rate
similar
except
made
dmd
patient
inde
although
life
extend
around
year
respiratori
assist
qualiti
life
past
year
old
progress
deterior
becom
total
unabl
move
eat
eventu
even
unabl
control
electr
wheelchair
parent
feed
chang
diaper
turn
bed
sever
time
night
although
mt
current
aim
prevent
death
may
permit
patient
improv
strength
sever
muscl
therebi
enabl
achiev
greater
autonomi
greatli
justifi
es
risk
associ
immunosuppress
numer
studi
last
year
accumul
signifi
cant
experi
tacrolimu
side
effect
list
center
tacrolimu
use
transplant
children
alreadi
quit
long
main
advers
effect
increas
epsteinbarr
viru
ebv
cmv
infect
one
clinic
trial
show
lymphoprolif
diseas
control
drug
treatment
comparison
tacrolimu
cyclosporin
children
age
year
undergo
heart
transplant
show
compar
nephrotox
two
group
year
transplant
anoth
investig
pediatr
liver
transplant
switch
patient
cyclosporin
tacrolimu
followup
show
main
side
effect
arteri
hypertens
liver
toxic
cosmet
damag
hypertroph
cardiomyopathi
associ
tacrolimu
use
three
small
bowel
two
liver
transplant
fi
children
age
month
followup
month
detect
treat
reduc
stop
tacrolimu
administr
one
hundr
three
pediatr
kidney
transplant
patient
younger
month
follow
month
treatment
oral
tacrolimu
three
patient
develop
lymphoprolif
diseas
due
ebv
infect
incid
type
ii
diabet
lower
children
tacrolimu
cyclosporin
tacrolimu
superior
cyclosporin
prevent
acut
kidney
reject
use
combin
azathioprin
corticosteroid
better
graft
surviv
year
investig
patient
age
month
heart
transplant
followup
month
show
frequent
side
effect
anemia
renal
toxic
hyperkalemia
gastrointestin
allerg
problem
late
death
mainli
caus
sever
infect
coronari
obstruct
lymphoprolif
diseas
mitochondri
myopathi
overview
demonstr
use
tacrolimu
infant
children
show
accept
rate
complic
consid
advantag
reject
control
effect
major
organ
transplant
area
consid
dmd
patient
otherwis
healthi
toler
tacrolimu
cohort
thu
even
better
furthermor
near
futur
immunosuppress
therapi
use
prevent
myoblast
reject
dmd
patient
might
modifi
ed
multitherapi
approach
lower
dose
compound
exclud
steroid
current
protocol
respons
relev
untoward
effect
avail
new
immunosuppress
compound
sirolimu
everolimu
specifi
c
antitumor
capac
also
evalu
reduc
oncolog
risk
may
also
possibl
develop
sustain
immunolog
toler
toward
donor
myoblast
hybrid
muscl
fi
ber
form
sinc
goal
achiev
mdx
mice
importantli
trial
type
diabet
involv
children
diseas
control
although
imperfectli
insulin
administr
progress
diseas
certainli
much
less
sever
dmd
inde
tacrolimu
current
use
children
treatment
autoimmun
diseas
myasthenia
gravi
nephriti
due
system
lupu
erythematosu
focal
segment
glomerulosclerosi
chronic
urticaria
resist
treatment
much
less
sever
dmd
incid
lymphoma
pediatr
renal
transplant
year
recent
immunosuppress
protocol
contain
tacrolimu
importantli
avail
evid
suggest
cumul
immunosuppress
specifi
c
drug
promot
develop
lymphoma
regard
renal
transplant
recipi
includ
children
receiv
combin
immunosuppress
drug
may
includ
tcell
deplet
monoclon
antibodi
increas
risk
lymphoma
incid
lymphoma
appear
much
lower
trial
use
calcineurin
inhibitor
singl
agent
children
exampl
children
averag
year
age
focal
segment
glomerulosclerosi
receiv
tacrolimu
plu
corticosteroid
month
none
develop
lymphoma
therefor
incid
lymphoma
dmd
patient
treat
tacrolimu
sole
immunosuppress
agent
exhibit
low
incid
malign
fact
heart
lung
transplant
recipi
develop
lymphoma
receiv
kidney
graft
fact
attribut
less
intens
immunosuppress
use
latter
case
begin
stem
cell
era
especi
central
nervou
system
diseas
goal
regener
neural
network
strongli
advoc
fi
eld
heart
patholog
myocardi
regener
acut
chronic
failur
infarct
activ
attempt
case
skelet
muscl
diseas
concept
repair
defect
muscl
fi
ber
possibl
introduc
skin
possibl
robot
arm
great
number
myoblast
close
proxim
mm
apart
futur
mt
administ
soon
fi
rst
symptom
muscular
failur
appear
two
reason
lower
number
cell
requir
due
underdevelop
muscular
mass
better
qualiti
viabl
muscular
tissu
colon
donor
myoblast
evid
transplant
myoblast
form
satellit
cell
repair
damag
muscl
fi
ber
thu
suggest
retransplant
muscl
necessari
mt
benefi
ts
therefor
last
lifetim
necessari
demonstr
improv
contractil
function
motil
improv
younger
patient
investig
defi
nite
confi
rm
feasibl
mt
current
effort
continu
make
mt
easi
safe
effect
standard
procedur
